On August 18, 2023, Haoyue Capital, a prominent industry investment bank focusing on Chinese healthcare, officially unveiled the "2023 7th Medical Health Investment Excellence List," featuring corporate categories, and bestowed upon OptoMedic the prestigious title of "Best Innovative Medical Device Company of the Year."

Renowned for its credibility and industry recognition since its inception in 2017, the Medical Health Investment Excellence List upholds principles of fairness, objectivity, and neutrality. Employing an anonymous voting system, with authoritative judges each casting one vote per company, the list meticulously evaluates various medical health investment funds' activities, transaction volumes, amounts, and returns. Drawing from publicly disclosed information and inputs from diverse institutions, it meticulously selects outstanding investment entities of the year.

Additionally, the Excellence List honors exceptional medical health enterprises across diverse sectors such as innovative medicine, medical devices, in vitro diagnostics (IVD) and life sciences, medical services, and smart healthcare. Its overarching goal is to forge a truly trustworthy and influential investment roster, setting new industry benchmarks, and fostering fresh opportunities for investment collaboration.

Established in 2013, Guangdong OptoMedic Technologies INC specializes in pioneering research and manufacturing of cutting-edge medical devices, particularly optical endoscopes. Over the years, OptoMedic has immersed itself in the entire technology spectrum, surmounting numerous endoscopy-related technical hurdles. It has comprehensively mastered pivotal technologies like minimally invasive visual technology, intelligent imaging platform technology, and mirror body design and processing technology in the high-end multifunctional endoscope domain, thereby constructing an endoscopic integrated technology platform centered around functional imaging.

Bolstered by a decade-long research and innovation journey in endoscopy, OptoMedic unveiled its inaugural domestic fully functional endoscope platform, OptoMedic | Stellar, in 2022. This revolutionary platform seamlessly integrates 4K image quality, fluorescence imaging, and 3D imaging capabilities. Independently researched and produced, the entire suite of image processors, cameras, cold light sources, and endoscope bodies solidifies OptoMedic's formidable core technological barrier. This milestone solidifies OptoMedic's status as a beacon of innovation in China's endoscopy landscape, poised to make waves globally.

In tandem with China's accelerated drive towards localizing high-end medical equipment, OptoMedic's timing for domestic substitution of imports couldn't be more opportune, with industry leaders primed for exponential growth. Presently, OptoMedic's products grace over 500 tertiary hospitals nationwide. Internationally, they've made significant inroads into countries like Germany, Italy, and Belgium, earning accolades from the International Society of Fluorescence-Guided Surgery (ISFGS), a revered academic body in the industry.

Embracing the ethos of "technological innovation, safeguarding life," OptoMedic remains steadfast in its commitment to fortify optical foundational technology and manufacturing prowess. It aims to amplify its core competitiveness and propagate scientific and technological breakthroughs across diverse niches. Moreover, OptoMedic eagerly anticipates collaborating hand in hand with Haoyue Capital and industry peers to steer industry trends and collectively foster the stable development of China's medical health sector.